Amiodarone Therapy for Atrial Rhythm Control: Insights Gained From a Single Center Experience

Autor:	David Schwartzman, Sheetal Chandhok
Rok vydání:	2007
Předmět:	Male medicine.medical_specialty Pulmonary toxicity Amiodarone Single Center Cohort Studies Physiology (medical) Internal medicine Atrial Fibrillation medicine Humans Aged Retrospective Studies Diminution business.industry Incidence (epidemiology) Atrial fibrillation Middle Aged Atrial Function medicine.disease Toxicity Cohort Cardiology Female Cardiology and Cardiovascular Medicine business Anti-Arrhythmia Agents Follow-Up Studies medicine.drug
Zdroj:	Journal of Cardiovascular Electrophysiology. 18:714-718
ISSN:	1540-8167 1045-3873
DOI:	10.1111/j.1540-8167.2007.00847.x
Popis:	Introduction: Amiodarone has been advocated as an effective “long-term” therapy for atrial rhythm control in patients with atrial fibrillation (AF). We sought to assess the sustainability of this therapeutic strategy. Methods and Results: Retrospective analysis of a consecutive, single-center cohort (n = 168) with symptomatic AF who were treated with amiodarone and followed for 3 years. The incidence of amiodarone cessation was evaluated at 1, 2, and 3 years and attributed principally to drug inefficacy, intolerance, or toxicity. A gradual diminution in the number of patients on therapy was observed, such that by 3 years, only 45% remained. This was attributable to inefficacy (25%), intolerance (12%), or toxicity (18%). Pulmonary toxicity was surprisingly common, occurring in at least 7% of patients. Conclusions: These data challenge the notion of amiodarone as a reasonable “destination” therapy for AF.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f082426867f7b741c676c9ba24bd5fb4 https://doi.org/10.1111/j.1540-8167.2007.00847.x Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.